1. Thiazolidinediones (TZDs) such as pioglitazone improve glycemic control by acting on a specific molecular target. Which of the following best identifies the direct pharmacological target of the TZD class?
A) The sulfonylurea receptor (SUR1) on the pancreatic beta-cell membrane, which closes ATP-sensitive potassium channels
B) PPAR-gamma (peroxisome proliferator-activated receptor gamma), a ligand-activated nuclear transcription factor
C) The sodium-glucose cotransporter-2 (SGLT-2) in the proximal renal tubule
D) The dipeptidyl peptidase-4 (DPP-4) enzyme that degrades incretin hormones
E) The brush-border alpha-glucosidase enzymes of the small intestine
ANSWER: B
Rationale:
TZDs are agonists at PPAR-gamma (peroxisome proliferator-activated receptor gamma), a ligand-activated nuclear transcription factor expressed predominantly in adipose tissue but also in skeletal muscle, liver, macrophages, and vascular endothelium. By activating PPAR-gamma, TZDs reprogram cellular metabolic gene expression toward enhanced insulin sensitivity, making them the only oral antidiabetic class that targets insulin resistance at the nuclear transcriptional level.
Option A: Option A is incorrect because the sulfonylurea receptor (SUR1) is the target of sulfonylureas and meglitinides, which are insulin secretagogues, not the target of TZDs.
Option C: Option C is incorrect because SGLT-2 in the proximal renal tubule is the target of the gliflozin class, an entirely separate mechanism.
Option D: Option D is incorrect because the DPP-4 enzyme is the target of the gliptin class, which enhances incretin action rather than activating a nuclear receptor.
Option E: Option E is incorrect because brush-border alpha-glucosidase enzymes are the target of acarbose and miglitol, which act in the intestinal lumen rather than on a nuclear transcription factor.
2. A resident is comparing the fundamental mechanisms of oral antidiabetic drug classes. Which statement correctly describes how thiazolidinediones (TZDs) lower blood glucose relative to the sulfonylureas?
A) TZDs and sulfonylureas both stimulate glucose-dependent insulin secretion from beta cells
B) TZDs block renal glucose reabsorption while sulfonylureas slow intestinal carbohydrate absorption
C) TZDs improve insulin sensitivity in peripheral tissues, whereas sulfonylureas stimulate insulin secretion
D) TZDs and sulfonylureas both act primarily by suppressing hepatic glucagon release
TZDs are insulin sensitizers: they reprogram gene expression via PPAR-gamma (peroxisome proliferator-activated receptor gamma) to enhance insulin-stimulated glucose uptake in skeletal muscle, redistribute lipid away from ectopic depots, and improve hepatic insulin sensitivity, without stimulating insulin secretion. Sulfonylureas, by contrast, are secretagogues that stimulate insulin release from beta cells. This distinction is fundamental: TZDs are the only oral class that directly targets insulin resistance.
Option A: Option A is incorrect because TZDs do not stimulate insulin secretion at all, and sulfonylurea secretion is not glucose-dependent.
Option B: Option B is incorrect because it describes SGLT-2 inhibitors and alpha-glucosidase inhibitors, not TZDs or sulfonylureas.
Option D: Option D is incorrect because neither class acts primarily by suppressing hepatic glucagon release.
Option E: Option E is incorrect because incretin degradation is the domain of DPP-4 (dipeptidyl peptidase-4) inhibitors, not TZDs or sulfonylureas.
3. A patient is started on sitagliptin for type 2 diabetes. Which of the following best describes the mechanism by which DPP-4 (dipeptidyl peptidase-4) inhibitors lower blood glucose?
A) They block the enzyme that degrades the incretin hormones GLP-1 and GIP, enhancing endogenous incretin action
B) They directly bind the GLP-1 (glucagon-like peptide-1) receptor on beta cells as receptor agonists
C) They increase renal excretion of glucose by inhibiting tubular reabsorption
D) They activate PPAR-gamma to enhance peripheral insulin sensitivity
E) They close beta-cell ATP-sensitive potassium channels to trigger insulin release
ANSWER: A
Rationale:
DPP-4 (dipeptidyl peptidase-4) inhibitors, also called gliptins, competitively inhibit the DPP-4 enzyme, the serine protease that rapidly cleaves and inactivates the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By blocking this degradation, gliptins extend the half-life of endogenous incretins and raise their postprandial concentrations, enhancing glucose-dependent insulin secretion.
Option B: Option B is incorrect because gliptins do not directly bind the GLP-1 receptor; that is the mechanism of injectable GLP-1 receptor agonists, which produce a much larger incretin effect.
Option C: Option C is incorrect because increased renal glucose excretion describes SGLT-2 inhibitors.
Option D: Option D is incorrect because PPAR-gamma activation is the mechanism of TZDs, not gliptins.
Option E: Option E is incorrect because closing beta-cell ATP-sensitive potassium channels describes the secretagogue action of sulfonylureas and meglitinides.
4. A 78-year-old patient with type 2 diabetes and a history of falls is being considered for a DPP-4 (dipeptidyl peptidase-4) inhibitor. Why do gliptins carry a low risk of hypoglycemia when used as monotherapy?
A) They are eliminated so rapidly that therapeutic drug levels are rarely sustained
B) They suppress endogenous insulin secretion entirely, preventing any drop in glucose
C) They stimulate counter-regulatory glucagon release that offsets any fall in glucose
D) Their incretin-mediated insulin secretion is glucose-dependent and ceases as glucose normalizes
E) They act only in the intestinal lumen and have no effect on systemic insulin secretion
ANSWER: D
Rationale:
The incretin system amplifies insulin secretion in a glucose-dependent manner, meaning incretin-potentiated insulin release is extinguished as blood glucose returns toward normal. Because DPP-4 (dipeptidyl peptidase-4) inhibitors work by enhancing this glucose-dependent incretin signal, the insulin secretion they promote ceases as glucose normalizes, giving them a categorically safer hypoglycemia profile than sulfonylureas. This makes them well suited to elderly patients in whom hypoglycemia carries a high risk of falls.
Option A: Option A is incorrect because gliptins maintain effective inhibition across the dosing interval; their hypoglycemia safety comes from glucose-dependence, not rapid elimination.
Option B: Option B is incorrect because gliptins enhance rather than suppress insulin secretion.
Option C: Option C is incorrect because GLP-1 (glucagon-like peptide-1) actually suppresses glucagon in a glucose-dependent manner rather than stimulating counter-regulatory glucagon release.
Option E: Option E is incorrect because that statement describes alpha-glucosidase inhibitors; gliptins act systemically to potentiate insulin secretion.
5. Acarbose is prescribed for a patient with predominantly postprandial hyperglycemia. Which mechanism explains how alpha-glucosidase inhibitors (AGIs) reduce post-meal glucose excursions?
A) They stimulate glucose-dependent insulin secretion from pancreatic beta cells
B) They increase peripheral insulin sensitivity through PPAR-gamma activation
C) They enhance the half-life of endogenous incretin hormones
D) They promote urinary glucose excretion by blocking renal reabsorption
E) They competitively inhibit brush-border alpha-glucosidase enzymes, slowing complex-carbohydrate digestion
ANSWER: E
Rationale:
Dietary complex carbohydrates must be hydrolyzed to monosaccharides by alpha-glucosidase enzymes (maltase, sucrase, isomaltase, glucoamylase) on the brush border of small-intestinal enterocytes before they can be absorbed. Acarbose and miglitol competitively inhibit these enzymes, binding the active site with higher affinity than the natural oligosaccharide substrates. The result is delayed and reduced monosaccharide generation, attenuating postprandial glucose excursions without stimulating insulin secretion or altering insulin sensitivity.
Option A: Option A is incorrect because AGIs do not stimulate insulin secretion; that is the secretagogue mechanism.
Option B: Option B is incorrect because PPAR-gamma activation describes the TZD class.
Option C: Option C is incorrect because enhancing incretin half-life describes DPP-4 (dipeptidyl peptidase-4) inhibitors.
Option D: Option D is incorrect because promoting urinary glucose excretion describes SGLT-2 inhibitors, not the luminal action of AGIs.
6. A patient taking acarbose reports bothersome flatulence, bloating, and abdominal discomfort. What is the mechanistic basis of these gastrointestinal adverse effects?
A) Undigested oligosaccharides reach the colon and are fermented by colonic bacteria, producing gas
B) Direct irritation of the gastric mucosa by the unabsorbed parent drug
C) Systemic accumulation of the drug causing autonomic dysmotility of the bowel
E) Bile acid malabsorption secondary to inhibition of ileal transporters
ANSWER: A
Rationale:
Because alpha-glucosidase inhibitors slow proximal carbohydrate digestion, a portion of the carbohydrate load passes undigested into the distal small intestine and colon, where colonic bacteria ferment the oligosaccharides into short-chain fatty acids and gas. This fermentation is the direct mechanistic basis of the flatulence, bloating, diarrhea, and abdominal discomfort that characterize AGI (alpha-glucosidase inhibitor) use and limit tolerability.
Option B: Option B is incorrect because the effect is not gastric mucosal irritation; acarbose acts in the intestinal lumen and the symptoms arise distally.
Option C: Option C is incorrect because acarbose has essentially no systemic absorption and does not cause autonomic dysmotility.
Option D: Option D is incorrect because AGIs do not increase pancreatic enzyme secretion; they inhibit brush-border enzymes.
Option E: Option E is incorrect because the mechanism is colonic carbohydrate fermentation, not bile acid malabsorption from ileal transporter inhibition.
7. A patient started on pioglitazone returns at two weeks frustrated that the drug "isn't working yet." Which statement about the onset of glycemic effect of thiazolidinediones (TZDs) is correct?
A) Maximal glycemic effect occurs within hours of the first dose, like a secretagogue
B) The drug has no glycemic effect unless combined with insulin from the outset
C) Glycemic benefit appears only after the drug induces significant weight loss
D) Maximal glycemic effect is delayed 6 to 12 weeks because it depends on changes in gene expression
E) The delay reflects slow renal accumulation of an active metabolite over several months
ANSWER: D
Rationale:
TZDs act through PPAR-gamma (peroxisome proliferator-activated receptor gamma)-driven changes in gene expression and protein synthesis, so their maximal glycemic effect is delayed 6 to 12 weeks. This time course is distinctly different from secretagogues or metformin and should be explained to patients so that therapy is not abandoned prematurely.
Option A: Option A is incorrect because TZDs do not produce a rapid, hours-scale effect; that pattern describes secretagogues.
Option B: Option B is incorrect because TZDs have an independent glycemic effect and do not require concurrent insulin.
Option C: Option C is incorrect because TZDs typically cause weight gain rather than weight loss, and the glycemic benefit is not contingent on weight reduction.
Option E: Option E is incorrect because the delay reflects the time required for transcriptional changes, not slow renal accumulation of a metabolite.
8. A patient with type 2 diabetes and stage 4 chronic kidney disease (CKD) needs a DPP-4 (dipeptidyl peptidase-4) inhibitor. Which agent is preferred because it requires no renal dose adjustment at any level of kidney function?
A) Saxagliptin
B) Linagliptin
C) Sitagliptin
D) Alogliptin
E) All gliptins require the same fixed dose reduction in CKD
ANSWER: B
Rationale:
Linagliptin is eliminated primarily by biliary and fecal excretion of unchanged drug rather than renal clearance, so it requires no renal dose adjustment at any severity of chronic kidney disease (CKD), making it the preferred gliptin in renal impairment.
Option A: Option A is incorrect because saxagliptin is primarily renally excreted and requires dose reduction to 2.5 mg when the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2.
Option C: Option C is incorrect because sitagliptin is primarily renally excreted and requires progressive dose reduction (for example, 25 mg daily at low eGFR).
Option D: Option D is incorrect because alogliptin is also primarily renally excreted and requires dose reduction as eGFR falls.
Option E: Option E is incorrect because the gliptins do not share a single fixed reduction; linagliptin is the specific exception requiring no adjustment.
9. When counseling a patient starting acarbose, what is the correct instruction regarding timing of administration relative to meals?
A) Take the dose 30 to 60 minutes before each meal on an empty stomach
B) Take the dose at bedtime, independent of meals
C) Take the dose with the first bite of each main meal
D) Take a single daily dose in the morning regardless of meal timing
E) Take the dose two hours after each meal to target late postprandial glucose
ANSWER: C
Rationale:
Acarbose and miglitol must be administered with the first bite of each main meal, because their competitive inhibition of brush-border alpha-glucosidases must be present in the intestinal lumen at the moment carbohydrate substrates arrive. Dosing with the meal ensures the drug is positioned to act on the incoming carbohydrate load.
Option A: Option A is incorrect because taking the dose well before the meal on an empty stomach misaligns drug presence with substrate arrival and is not the recommended timing.
Option B: Option B is incorrect because bedtime dosing independent of meals would not place the inhibitor where carbohydrate is being digested.
Option D: Option D is incorrect because a single morning dose ignores the meal-by-meal requirement for these luminal agents.
Option E: Option E is incorrect because dosing two hours after the meal would miss the carbohydrate digestion window the drug is meant to attenuate.
10. Pioglitazone and rosiglitazone differ in their effects on the lipid panel. Which statement best explains why pioglitazone produces a more favorable lipid profile?
A) Pioglitazone is a pure PPAR-gamma agonist, whereas rosiglitazone activates PPAR-alpha
B) Pioglitazone inhibits intestinal cholesterol absorption directly
C) Pioglitazone lowers LDL-C by upregulating hepatic LDL receptors
D) Pioglitazone has no metabolic effect on lipids; the difference is an artifact of dosing
E) Pioglitazone activates both PPAR-gamma and, to a lesser degree, PPAR-alpha, improving the lipid profile
ANSWER: E
Rationale:
Pioglitazone activates both PPAR-gamma (peroxisome proliferator-activated receptor gamma) and, to a lesser degree, PPAR-alpha (peroxisome proliferator-activated receptor alpha, the hepatic lipid-oxidation receptor). This dual activity produces a more favorable lipid profile than rosiglitazone: pioglitazone modestly raises HDL-C (high-density lipoprotein cholesterol) and lowers triglycerides, whereas rosiglitazone raises both LDL-C (low-density lipoprotein cholesterol) and HDL-C without the triglyceride-lowering benefit.
Option A: Option A is incorrect because it inverts the pharmacology; pioglitazone is the agent with added PPAR-alpha activity, not rosiglitazone, and pioglitazone is not a pure PPAR-gamma agonist.
Option B: Option B is incorrect because pioglitazone does not act by inhibiting intestinal cholesterol absorption.
Option C: Option C is incorrect because the favorable lipid effect is driven by dual PPAR activity, not by hepatic LDL-receptor upregulation.
Option D: Option D is incorrect because the lipid difference is a genuine pharmacological effect, not a dosing artifact.
11. A patient on pioglitazone develops peripheral edema and a 3 kg weight gain. Which mechanism underlies the fluid retention caused by thiazolidinediones (TZDs)?
A) PPAR-gamma-mediated upregulation of the epithelial sodium channel (ENaC) in the renal collecting duct, increasing sodium reabsorption
B) Direct stimulation of aldosterone secretion from the adrenal cortex
C) Inhibition of atrial natriuretic peptide release from the heart
D) A sharp rise in systemic blood pressure driving capillary fluid shift
E) Impaired hepatic albumin synthesis producing reduced oncotic pressure
ANSWER: A
Rationale:
TZD fluid retention is a class effect arising from PPAR-gamma (peroxisome proliferator-activated receptor gamma)-mediated upregulation of the epithelial sodium channel (ENaC) in the collecting duct of the kidney, which increases renal sodium reabsorption and expands extracellular fluid volume. This mechanism is independent of blood pressure and aldosterone, and clinically produces weight gain, peripheral edema, and an increased risk of heart failure hospitalization.
Option B: Option B is incorrect because the effect is explicitly independent of aldosterone; TZDs do not act by stimulating adrenal aldosterone secretion.
Option C: Option C is incorrect because the mechanism is enhanced distal sodium reabsorption via ENaC, not inhibition of atrial natriuretic peptide.
Option D: Option D is incorrect because the sodium retention is independent of blood pressure and is not driven by a hypertensive capillary shift.
Option E: Option E is incorrect because TZD edema reflects sodium and volume retention, not reduced oncotic pressure from impaired albumin synthesis.
12. A patient with type 2 diabetes and established heart failure needs a DPP-4 (dipeptidyl peptidase-4) inhibitor. Which statement correctly reflects the heart failure data across the gliptin class?
A) All gliptins increase heart failure hospitalization to a similar degree
B) Sitagliptin uniquely increased heart failure hospitalization in its cardiovascular outcome trial
C) No gliptin has ever shown any heart failure signal in outcome trials
D) Saxagliptin increased heart failure hospitalization in SAVOR-TIMI 53, while sitagliptin and linagliptin did not show this signal
E) Linagliptin carries the strongest heart failure signal and is contraindicated in heart failure
ANSWER: D
Rationale:
In the SAVOR-TIMI 53 cardiovascular outcome trial, saxagliptin increased heart failure hospitalization by 27 percent compared with placebo (hazard ratio 1.27; p=0.007), and a directionally similar signal was seen with alogliptin in EXAMINE. By contrast, sitagliptin in TECOS and linagliptin in CARMELINA showed no excess heart failure signal. The practical implication is that sitagliptin or linagliptin are preferred within the class for patients with established heart failure.
Option A: Option A is incorrect because the heart failure risk is agent-specific, not a uniform class effect.
Option B: Option B is incorrect because sitagliptin showed no increase in heart failure hospitalization in TECOS; the signal belongs to saxagliptin and alogliptin.
Option C: Option C is incorrect because a heart failure signal clearly was identified, specifically with saxagliptin and alogliptin.
Option E: Option E is incorrect because linagliptin showed no excess heart failure signal and is among the preferred agents in heart failure, not contraindicated.
13. A patient takes acarbose together with a sulfonylurea and develops hypoglycemia. Why must this hypoglycemia be treated with glucose rather than table sugar (sucrose)?
A) Sucrose paradoxically lowers blood glucose further in patients on acarbose
B) Acarbose inhibits the breakdown of sucrose into absorbable monosaccharides, so sucrose will not raise glucose adequately
C) Sucrose triggers additional insulin release that worsens the hypoglycemia
D) Glucose tablets are simply more palatable, with no pharmacological difference
E) Acarbose blocks intestinal glucose transporters, so only intravenous dextrose will work
ANSWER: B
Rationale:
Alpha-glucosidase inhibitors prevent the brush-border hydrolysis of sucrose (and other complex carbohydrates) into absorbable monosaccharides, so ingesting sucrose during hypoglycemia will not produce adequate glucose recovery. Hypoglycemia in a patient combining an AGI (alpha-glucosidase inhibitor) with a secretagogue or insulin must therefore be treated with glucose itself (tablets or gel), which is absorbed directly and does not require alpha-glucosidase digestion.
Option A: Option A is incorrect because sucrose does not lower glucose further; it simply fails to raise it efficiently because its digestion is blocked.
Option C: Option C is incorrect because the problem is impaired sucrose absorption, not extra insulin release.
Option D: Option D is incorrect because there is a genuine pharmacological reason, not merely palatability.
Option E: Option E is incorrect because AGIs inhibit brush-border digestive enzymes rather than glucose transporters, and oral glucose is absorbed normally, so intravenous dextrose is not required for routine treatment.
14. A 64-year-old postmenopausal woman with osteopenia is being considered for a thiazolidinedione (TZD). Which statement about TZD bone effects is correct?
A) TZDs increase bone mineral density and reduce fracture risk
B) Bone fracture risk is unique to rosiglitazone and absent with pioglitazone
C) TZDs increase fracture risk as a class effect, particularly at distal sites in postmenopausal women
D) Fracture risk applies only to men, not to postmenopausal women
E) The fracture risk is limited to vertebral compression fractures
ANSWER: C
Rationale:
TZD bone fracture risk is a class effect with well-established epidemiological and mechanistic support: PPAR-gamma (peroxisome proliferator-activated receptor gamma) activation favors adipocyte over osteoblast differentiation and increases osteoclast activity, reducing bone mineral density. Large cohort studies show a 40 to 60 percent increased fracture risk at distal extremity sites (wrist, foot, ankle) in postmenopausal women, with a more modest and less consistent signal in men.
Option A: Option A is incorrect because TZDs reduce, not increase, bone mineral density and raise fracture risk.
Option B: Option B is incorrect because both pioglitazone and rosiglitazone carry the same bone fracture liability; it is not unique to rosiglitazone.
Option D: Option D is incorrect because postmenopausal women carry the clearest excess risk, with the signal in men being weaker.
Option E: Option E is incorrect because the characteristic fractures occur at distal extremity sites such as the wrist, foot, and ankle, not predominantly vertebral compression fractures.
15. A patient on saxagliptin is started on clarithromycin, a potent CYP3A4 (cytochrome P450 3A4) inhibitor. Which statement about gliptin drug interactions is correct?
A) Saxagliptin is a CYP3A4 substrate, so its dose should be reduced (from 5 mg to 2.5 mg) with potent CYP3A4 inhibitors
B) Sitagliptin requires dose reduction with all macrolide antibiotics
C) Linagliptin must be discontinued whenever any CYP3A4 inhibitor is co-administered
D) All gliptins are potent CYP3A4 inhibitors and raise levels of co-administered drugs
E) Gliptins have no clinically relevant drug interactions of any kind
ANSWER: A
Rationale:
Saxagliptin is metabolized as a CYP3A4 (cytochrome P450 3A4) substrate, so co-administration of a potent CYP3A4 inhibitor (such as ketoconazole, clarithromycin, or ritonavir) requires reducing the saxagliptin dose from 5 mg to 2.5 mg. Among the gliptins, this is the principal clinically meaningful cytochrome P450 interaction.
Option B: Option B is incorrect because sitagliptin is not significantly metabolized by cytochrome P450 enzymes and has a minimal interaction profile.
Option C: Option C is incorrect because linagliptin has minimal clinically significant drug interactions and does not require discontinuation with CYP3A4 inhibitors.
Option D: Option D is incorrect because gliptins are substrates in the relevant case (saxagliptin), not potent CYP3A4 inhibitors that raise other drug levels.
Option E: Option E is incorrect because saxagliptin clearly does have a clinically relevant CYP3A4 interaction, even though most other gliptins have minimal interactions.
16. Acarbose has essentially no systemic absorption of the parent drug, yet it is contraindicated in significant renal impairment. What best explains this contraindication?
A) The parent drug is renally cleared and accumulates to toxic levels in kidney disease
B) Acarbose directly damages the renal tubules through a nephrotoxic metabolite
C) Renal impairment markedly increases systemic absorption of the intact parent drug
D) Acarbose causes hyperkalemia that becomes dangerous when renal clearance falls
E) Bacterial degradation products of acarbose are absorbed and renally excreted, accumulating when kidney function is impaired
ANSWER: E
Rationale:
Although less than 2 percent of an acarbose dose reaches the systemic circulation as parent drug, degradation products generated by bacterial cleavage in the colon are absorbed and excreted renally. In significant renal impairment (for example, serum creatinine above 2.0 mg/dL or estimated glomerular filtration rate below 30 mL/min/1.73m2), these metabolites can accumulate, which is why acarbose is contraindicated despite the parent drug not being renally cleared.
Option A: Option A is incorrect because it is the metabolites, not the minimally absorbed parent drug, that accumulate.
Option B: Option B is incorrect because the contraindication reflects metabolite accumulation rather than direct tubular nephrotoxicity.
Option C: Option C is incorrect because renal impairment does not markedly increase absorption of the intact parent compound, which remains a luminal agent.
Option D: Option D is incorrect because the concern is accumulation of renally excreted metabolites, not acarbose-induced hyperkalemia.
17. A patient with type 2 diabetes and biopsy-proven non-alcoholic steatohepatitis (NASH) is being evaluated for an oral antidiabetic with benefit beyond glycemia. Which agent has consistent randomized trial evidence of histological improvement in NASH?
A) Sitagliptin
B) Acarbose
C) Saxagliptin
D) Pioglitazone
E) Miglitol
ANSWER: D
Rationale:
Pioglitazone is the only oral antidiabetic agent with consistent randomized trial evidence of histological improvement in NASH, reducing hepatic steatosis, lobular inflammation, and hepatocyte ballooning, with some evidence of fibrosis regression. Its PPAR-gamma (peroxisome proliferator-activated receptor gamma)-mediated reduction of hepatic lipotoxicity and insulin sensitization directly targets the core disease mechanism, and current guidelines support its use in patients with type 2 diabetes and biopsy-proven NASH.
Option A: Option A is incorrect because sitagliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor, lacks randomized evidence of NASH histological benefit.
Option B: Option B is incorrect because acarbose, an alpha-glucosidase inhibitor, acts in the intestinal lumen and has no established NASH histological benefit.
Option C: Option C is incorrect because saxagliptin, another gliptin, does not have NASH histological efficacy data.
Option E: Option E is incorrect because miglitol, an alpha-glucosidase inhibitor, likewise has no role in NASH treatment.
18. The cardiovascular safety trajectories of the two available thiazolidinediones (TZDs) diverged in the 2000s. Which statement correctly summarizes this divergence?
A) Both agents showed clear cardiovascular benefit, and the distinction is purely historical
B) Rosiglitazone was associated with increased myocardial infarction risk, whereas pioglitazone showed a cardiovascular-protective signal in PROactive
C) Pioglitazone was withdrawn for cardiovascular harm while rosiglitazone became the preferred agent
D) Both agents were permanently removed from the market for cardiovascular toxicity
E) Rosiglitazone reduced myocardial infarction while pioglitazone increased it
ANSWER: B
Rationale:
Rosiglitazone's cardiovascular risk was raised by a 2007 meta-analysis showing a statistically significant increase in myocardial infarction risk, prompting severe prescribing restrictions, and it remains rarely used. Pioglitazone, by contrast, showed a cardiovascular-protective signal in the PROactive trial, with a reduction in the composite secondary endpoint of all-cause mortality, myocardial infarction (MI), and stroke. The mechanistic basis is pioglitazone's favorable dual PPAR-alpha/gamma effect on the atherogenic lipid profile.
Option A: Option A is incorrect because the two agents diverged sharply; they did not both show clear cardiovascular benefit.
Option C: Option C is incorrect because it inverts reality: pioglitazone was not withdrawn for cardiovascular harm, and rosiglitazone is not the preferred agent.
Option D: Option D is incorrect because neither agent was permanently removed from the market for cardiovascular toxicity.
Option E: Option E is incorrect because it reverses the directionality; rosiglitazone carried the increased myocardial infarction signal, not pioglitazone.
19. A patient with NYHA (New York Heart Association) class III heart failure has type 2 diabetes inadequately controlled on metformin. Which statement about thiazolidinedione (TZD) use is correct?
A) TZDs are first-line add-on therapy in advanced heart failure because they reduce volume overload
B) TZDs are safe in any NYHA class provided a loop diuretic is co-prescribed
C) TZDs are contraindicated in NYHA class III or IV heart failure
D) TZDs are contraindicated only in NYHA class I and II, but safe in class III and IV
E) TZDs have no relationship to heart failure status and may be used freely
ANSWER: C
Rationale:
TZDs cause renal sodium retention and volume expansion and carry a 2 to 3-fold increased risk of heart failure hospitalization, so they are contraindicated in NYHA (New York Heart Association) class III or IV heart failure and should be used with extreme caution in class I or II. A class III patient therefore should not receive a TZD.
Option A: Option A is incorrect because TZDs worsen volume overload rather than reduce it and are not appropriate add-on therapy in advanced heart failure.
Option B: Option B is incorrect because co-prescribing a loop diuretic does not make TZDs safe in advanced heart failure; the contraindication in class III/IV stands.
Option D: Option D is incorrect because it inverts the rule: the contraindication applies to class III/IV, while class I/II warrants caution.
Option E: Option E is incorrect because TZD use is directly tied to heart failure status and cannot be used freely.
20. Troglitazone, the first thiazolidinedione (TZD) approved, was withdrawn worldwide in 2000. Which statement best explains why troglitazone caused hepatotoxicity that pioglitazone and rosiglitazone do not?
A) Troglitazone contains a tocopherol (vitamin E) moiety that is metabolized to a reactive quinone capable of causing idiosyncratic hepatic injury
B) Troglitazone was the only TZD that activated PPAR-gamma, and that activation directly damages hepatocytes
C) Troglitazone accumulates in the liver because it is not metabolized at all
D) Troglitazone hepatotoxicity was strictly dose-related and predictable from clinical trials
E) Pioglitazone and rosiglitazone are not metabolized in the liver, so only troglitazone reaches hepatocytes
ANSWER: A
Rationale:
Unlike pioglitazone and rosiglitazone, troglitazone contains a tocopherol (vitamin E, alpha-tocopherol) moiety that undergoes oxidative metabolism to a reactive quinone intermediate capable of forming protein adducts and causing mitochondrial dysfunction. This produced idiosyncratic hepatotoxicity affecting roughly 1 in 50,000 patients, which was undetectable in pre-approval trials and led to withdrawal by 2000. Pioglitazone and rosiglitazone lack this moiety and do not generate the toxic metabolite.
Option B: Option B is incorrect because PPAR-gamma (peroxisome proliferator-activated receptor gamma) activation is shared by all TZDs and does not directly cause the hepatotoxicity; the structural tocopherol metabolism is the key.
Option C: Option C is incorrect because troglitazone was metabolized; the problem was a reactive metabolite, not absence of metabolism.
Option D: Option D is incorrect because the hepatotoxicity was idiosyncratic and not dose-related at therapeutic doses, which is precisely why trials missed it.
Option E: Option E is incorrect because pioglitazone and rosiglitazone are in fact hepatically metabolized, yet do not generate the troglitazone toxic metabolite.
21. The pancreatitis signal associated with incretin-based therapies prompted intense scrutiny. What did the large dedicated cardiovascular outcome trials ultimately show about pancreatitis risk with DPP-4 (dipeptidyl peptidase-4) inhibitors?
A) They confirmed a large, statistically significant increase in pancreatitis, leading to class withdrawal
B) They showed pancreatitis risk only in patients without prior diabetes
C) Across more than 45,000 patients, they showed no statistically significant increase in confirmed acute pancreatitis versus placebo
D) They were never able to assess pancreatitis because the trials were too small
E) They demonstrated that DPP-4 inhibitors prevent pancreatitis compared with placebo
ANSWER: C
Rationale:
The dedicated cardiovascular outcome trials (SAVOR-TIMI 53, EXAMINE, TECOS, and ELIXA) collectively enrolled more than 45,000 patients and showed no statistically significant increase in confirmed acute pancreatitis with DPP-4 (dipeptidyl peptidase-4) inhibitors or liraglutide compared with placebo. The FDA concluded that pancreatitis does not represent a class-level pharmacological hazard, though it remains a listed precaution given mechanistic plausibility.
Option A: Option A is incorrect because the trials did not confirm a large significant increase, and the class was not withdrawn.
Option B: Option B is incorrect because the trials did not show a pancreatitis signal confined to patients without prior diabetes.
Option D: Option D is incorrect because the trials were large and specifically powered enough to assess this safety endpoint across tens of thousands of patients.
Option E: Option E is incorrect because the data showed no significant difference, not a protective effect against pancreatitis.
22. In the current treatment framework, which clinical scenario best represents the well-defined niche for a DPP-4 (dipeptidyl peptidase-4) inhibitor as second-line therapy?
A) An elderly patient with chronic kidney disease in whom hypoglycemia avoidance and weight neutrality are primary concerns
B) A young patient with established atherosclerotic cardiovascular disease seeking the agent with the strongest proven cardiovascular benefit
C) A patient with severe symptomatic heart failure needing volume reduction
D) A patient requiring substantial weight loss as a primary treatment goal
E) A patient with predominantly fasting hyperglycemia and no postprandial elevation
ANSWER: A
Rationale:
DPP-4 (dipeptidyl peptidase-4) inhibitors occupy a well-defined niche as second- or third-line agents where hypoglycemia avoidance and weight neutrality are primary concerns. They are particularly well-suited to elderly patients (in whom hypoglycemia raises fall and cardiovascular risk) and to patients with chronic kidney disease (with linagliptin requiring no dose adjustment), making the elderly CKD patient the prototypical scenario.
Option B: Option B is incorrect because patients seeking the strongest proven cardiovascular benefit are directed to SGLT-2 inhibitors or GLP-1 (glucagon-like peptide-1) receptor agonists, not gliptins, which are cardiovascular-neutral.
Option C: Option C is incorrect because gliptins do not reduce volume, and certain agents carry a heart failure hospitalization signal, so they are not the choice for severe heart failure needing volume reduction.
Option D: Option D is incorrect because gliptins are weight-neutral and do not produce the substantial weight loss that would be the goal in that scenario.
Option E: Option E is incorrect because the postprandial-targeting niche belongs to alpha-glucosidase inhibitors; gliptins are not specifically selected for isolated fasting hyperglycemia.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.